The trial compared Spravato (esketamine nasal spray) to quetiapine extended-release, both in combination with a continuing SSRI or SNRI.
Bebtelovimab is currently authorized for emergency use for the treatment of mild to moderate COVID-19 in adults and pediatric patients.
Dupixent single-dose prefilled pens feature a hidden needle and single-press auto-injection.
The approval was based on data from the SELECT-AXIS 2 trial that included adults with active nr-axSpA who had an inadequate response or intolerance to TNF blocker therapy.
Findings showed that the booster dose elicited robust antibody responses comparable to, or exceeding levels associated with the efficacy data in the primary series of the vaccine.
The approval was based on data from the phase 3 PRIME and PRIME2 trials.
Results from both studies demonstrated that ruxolitinib met the primary endpoint with a greater proportion of patients achieving F-VASI75 at week 24.
The approval was based on data from 2 multicenter, randomized, double-blind, vehicle-controlled phase 3 trials.
Each gram of lotion contains 5mg of ivermectin, the same as the prescription strength.
Vyne Therapeutics announced the availability of Zilxi (minocycline) topical foam 1.5% for the treatment of inflammatory lesions of rosacea in adults.
